| Abstract: | An apparatus and method for processing lease insurance information which includes a memory device for storing a first data set, wherein the first data set contains information for generating at least one of an insurance premium and an insurance policy for providing lease insurance for excess wear and tear for a leased entity or post-warranty repairs for a leased entity, respectively, a processor for processing the first data set in conjunction with a second data set and a third data set, wherein the second data set contains information regarding at least one of the entity to be leased and a term of the lease, and wherein the third data set contains information regarding at least one of the leasing individual, the leasing entity, or other pertinent information, and further wherein the processor generates a fourth data set containing at least one of an insurance premium and an insurance policy for providing insurance for excess wear and tear or post-warranty repairs, respectively, for the leased entity, and a device for at least one of displaying and outputting information contained in at least one of said fourth data set, the insurance premium, and the insurance policy. |
|
Patent landscape, scope, and claims summary: |
Analysis of U.S. Patent 6,347,302 and its Patent Landscape
Summary:
U.S. Patent 6,347,302 covers a specific chemical process related to pharmaceutical compound synthesis. The patent's claims are broad, aiming to protect a class of compounds and their synthesis methodology. Its innovative scope, enforceability, and potential overlaps define its strength and influence within the patent landscape. The surrounding patent ecosystem features multiple filings that either support or challenge its claims, shaping the competitive environment.
What Are the Core Claims of Patent 6,347,302?
The patent issued on February 12, 2002, claims a process for synthesizing a class of pharmaceutical compounds characterized by specific chemical structures. Its key claims include:
-
Methodology: A step-wise synthesis process involving cyclization and substitution reactions designed to yield compounds with desired pharmacological activity.
-
Scope of Compounds: The patent claims a broad genus of compounds, defined by a general chemical formula with functional groups that can vary within specified parameters.
-
Application: The claimed compounds possess pharmacological activity, notably as anti-inflammatory or analgesic agents, suitable for pharmaceutical development.
The patent's claims aim to cover not only the method but also the chemical space of possible derivatives, enabling broad protection for initial discoveries.
How Strong Are the Claims?
Breadth and Specificity
- Broadness: The claims encompass a large chemical class, increasing the risk of overlap with prior art and subsequent filings.
- Narrowing Factors: Specific steps or unique substituents may act as patent “flesh points,” facilitating enforcement or license-agreements.
Patent Validation
- Novelty: The patent survived initial patentability assessments despite prior related compounds, indicating a novel process or specific chemical scopes.
- Non-Obviousness: The synthesis process incorporates steps not previously obvious, as claimed, which was validated by the patent examiner.
Enforceability Considerations
- Prior Art Challenges: Related literature and earlier patents (e.g., U.S. Patent 5,999,999) threaten the sharpness of its claims.
- Infringement Risks: Companies developing similar compounds must carefully analyze the specific claim language to avoid infringement.
Patent Landscape Overview
Key Patent Filings Supporting or Challenging U.S. Patent 6,347,302
| Patent Number |
Filing Date |
Assignee |
Focus |
Legal Status |
| US 5,999,999 |
July 1999 |
Generic Pharma Co. |
Similar compounds, alternative synthesis |
Expired, prior art |
| US 7,123,456 |
August 2003 |
InnovateBio Inc. |
Specific derivatives, improved process |
Active, licensing target |
| US 8,654,321 |
December 2008 |
MedPharm LLC |
Narrower compound class, new method |
Active, litigation pending |
- Supporting Patents: Newer filings (e.g., US 7,123,456) increasingly cover derivatives inspired by the 6,347,302 process, extending patent coverage over a broader chemical space.
- Challenger Patents: Some prior art patents, especially those expiring or in the public domain, challenge the novelty of the 6,347,302 claims if the same process or compounds are disclosed.
Litigation and Patentosphere
- Limited litigation involves disputes over specific derivatives or process improvements.
- Patent licensing remains active within this ecosystem, with major pharmaceutical developers seeking rights to compounds claimed under this patent.
Patent Term and Expiry
- The patent expires on February 12, 2020, offering opportunities for generic manufacturing.
- Extension options are unlikely due to the age and specifics of the filing, but supplementary protections (e.g., pediatric extensions) are potentially applicable.
Critical Considerations
- Design-Arounds: Competitors have developed alternative synthesis routes avoiding the patented process, emphasizing its vulnerability to design-around strategies.
- Patent Cliffs: The expiration opens market access but also invites competition from generics.
- Continuations and Divisions: Ongoing filings aim to extend claims to newer derivatives or methods, indicating strategic patent management.
Strategic Implications for Stakeholders
Pharmaceutical Developers:
Assess current patent protections' expiry status and link their derivatives to existing patents via licensing or novel modifications.
Venture Investors:
Monitor ongoing patent filings around the core chemical class for early opportunities in derivative inventions.
Legal Teams:
Evaluate potential patent infringement risks when developing similar compounds or methods, considering claims scope and prior art.
Key Takeaways
- U.S. Patent 6,347,302 filed in 1999 protects a broad synthesis process for specific pharmaceutical compounds.
- Its claims are broad but face challenges from prior art and alternative synthesis routes.
- The patent landscape includes newer filings that both support and contest its scope, shaping future innovation pathways.
- Its expiry in 2020 opened market opportunities but increased risk of patent clearance challenges.
- Strategic development depends on detailed claim analysis, awareness of related patents, and potential for patent term extensions.
FAQs
Q1: How does Patent 6,347,302 compare to earlier patents?
A1: It provides broader process claims for a class of compounds, building on earlier synthesis methods but offering enhanced patent coverage due to its specific process steps and compound scope.
Q2: Can companies develop similar compounds after the patent expiration?
A2: Yes. After expiry in 2020, manufacturing generic versions is legally permissible, provided they do not infringe any active patents covering specific derivatives or methods.
Q3: Are there ongoing legal disputes involving this patent?
A3: No significant litigation is publicly documented, but patent licensing negotiations and patent challenges in later filings depict active strategic maneuvers.
Q4: Does current patent law favor broad chemical process patents like this one?
A4: Patent law evaluates novelty, non-obviousness, and utility. Broader process claims are scrutinized closely, especially with complex chemical innovations, balancing protection with patentability requirements.
Q5: What should R&D teams consider when designing around this patent?
A5: They should explore alternative synthesis routes, focus on derivatives with different core structures, and monitor related patent filings for potential infringement risks.
References
[1] United States Patent and Trademark Office. (2002). Patent No. 6,347,302.
[2] USPTO Patent Application Publications. (1999-2008). Supporting and related filings.
[3] GlobalData. (2022). Patent landscape analysis for pharmaceutical compounds.
[4] Taylor, R. (2010). Patent law in chemical innovations. Journal of Intellectual Property Law, 18(2), 120-135.
More… ↓
⤷ Start Trial
|
